Premium
Pimavanserin responders in Alzheimer's psychosis also see benefit in agitation, aggression
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30667
Subject(s) - aggression , psychosis , medicine , disease , psychology , psychiatry , clinical psychology
Patients with Alzheimer's disease whose psychotic symptoms improved with use of pimavanserin also showed improvement in agitation and aggression compared with nonresponders to the treatment, a study has found. These differences on agitation and aggression also were apparent in patients with higher baseline levels of these symptoms, the researchers reported.